

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	"6150415".pn.	US-PGPUB; USPAT; EPO	OR	ON	2006/05/02 15:02
L2	1	"6531506".pn.	US-PGPUB; USPAT; EPO	OR	ON	2006/05/02 15:03
L3	1	"6693130".pn.	US-PGPUB; USPAT; EPO	OR	ON	2006/05/02 15:03

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptamxg1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \*      Welcome to STN International      \* \* \* \* \* \* \* \* \*

NEWS 1            Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2            "Ask CAS" for self-help around the clock  
NEWS 3 DEC 23     New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/  
                  USPAT2  
NEWS 4 JAN 13     IPC 8 searching in IFIPAT, IFIUDB, and IFICDB  
NEWS 5 JAN 13     New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to  
                  INPADOC  
NEWS 6 JAN 17     Pre-1988 INPI data added to MARPAT  
NEWS 7 JAN 17     IPC 8 in the WPI family of databases including WPIFV  
NEWS 8 JAN 30     Saved answer limit increased  
NEWS 9 FEB 21     STN AnaVist, Version 1.1, lets you share your STN AnaVist  
                  visualization results  
NEWS 10 FEB 22    The IPC thesaurus added to additional patent databases on STN  
NEWS 11 FEB 22    Updates in EPFULL; IPC 8 enhancements added  
NEWS 12 FEB 27    New STN AnaVist pricing effective March 1, 2006  
NEWS 13 FEB 28    MEDLINE/LMEDLINE reload improves functionality  
NEWS 14 FEB 28    TOXCENTER reloaded with enhancements  
NEWS 15 FEB 28    REGISTRY/ZREGISTRY enhanced with more experimental spectral  
                  property data  
NEWS 16 MAR 01    INSPEC reloaded and enhanced  
NEWS 17 MAR 03    Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 18 MAR 08    X.25 communication option no longer available after June 2006  
NEWS 19 MAR 22    EMBASE is now updated on a daily basis  
NEWS 20 APR 03    New IPC 8 fields and IPC thesaurus added to PATDPAPULL  
NEWS 21 APR 03    Bibliographic data updates resume; new IPC 8 fields and IPC  
                  thesaurus added in PCTFULL  
NEWS 22 APR 04    STN AnaVist \$500 visualization usage credit offered  
NEWS 23 APR 12    LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 24 APR 12    Improved structure highlighting in FQHIT and QHIT display  
                  in MARPAT  
NEWS 25 APR 12    Derwent World Patents Index to be reloaded and enhanced during  
                  second quarter; strategies may be affected  
  
NEWS EXPRESS    FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
                  CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
                  AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
                  V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
                  <http://download.cas.org/express/v8.0-Discover/>  
  
NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN       Welcome Banner and News Items  
NEWS IPC8        For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

**COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31**

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

FILE 'HOME' ENTERED AT 07:33:04 ON 02 MAY 2006

FILE 'CAPLUS' ENTERED AT 07:33:21 ON 02 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2006 VOL 144 ISS 19  
FILE LAST UPDATED: 1 May 2006 (20060501/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s us 2005-0222252/pn  
L1 1 US 2005-0222252/PN  
                 (US2005222252/PN)

=> sel rn  
E1 THROUGH E42 ASSIGNED

FULL ESTIMATED COST

2.49

2.70

FILE 'REGISTRY' ENTERED AT 07:33:36 ON 02 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 MAY 2006 HIGHEST RN 882489-85-2  
DICTIONARY FILE UPDATES: 1 MAY 2006 HIGHEST RN 882489-85-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> s el-e42  
1 162425-98-1/BI  
(162425-98-1/RN)  
1 184488-44-6/BI  
(184488-44-6/RN)  
1 197508-62-6/BI  
(197508-62-6/RN)  
1 200960-01-6/BI  
(200960-01-6/RN)  
1 2387-23-7/BI  
(2387-23-7/RN)  
1 2566-89-4/BI  
(2566-89-4/RN)  
1 402939-18-8/BI  
(402939-18-8/RN)  
1 479413-70-2/BI  
(479413-70-2/RN)  
1 564468-65-1/BI  
(564468-65-1/RN)  
1 776300-37-9/BI  
(776300-37-9/RN)  
1 866442-84-4/BI  
(866442-84-4/RN)  
1 866442-85-5/BI  
(866442-85-5/RN)  
1 866442-86-6/BI

(866442-86-6/RN)  
1 866442-87-7/BI  
(866442-87-7/RN)  
1 866442-88-8/BI  
(866442-88-8/RN)  
1 866442-89-9/BI  
(866442-89-9/RN)  
1 866442-90-2/BI  
(866442-90-2/RN)  
1 866442-91-3/BI  
(866442-91-3/RN)  
1 866442-92-4/BI  
(866442-92-4/RN)  
1 866442-93-5/BI  
(866442-93-5/RN)  
1 866442-94-6/BI  
(866442-94-6/RN)  
1 866442-95-7/BI  
(866442-95-7/RN)  
1 866442-96-8/BI  
(866442-96-8/RN)  
1 866442-97-9/BI  
(866442-97-9/RN)  
1 866442-98-0/BI  
(866442-98-0/RN)  
1 866442-99-1/BI  
(866442-99-1/RN)  
1 866443-00-7/BI  
(866443-00-7/RN)  
1 866443-01-8/BI  
(866443-01-8/RN)  
1 866443-02-9/BI  
(866443-02-9/RN)  
1 866443-03-0/BI  
(866443-03-0/RN)  
1 866443-04-1/BI  
(866443-04-1/RN)  
1 866443-05-2/BI  
(866443-05-2/RN)  
1 866443-06-3/BI  
(866443-06-3/RN)  
1 866443-07-4/BI  
(866443-07-4/RN)  
1 866443-08-5/BI  
(866443-08-5/RN)  
1 866443-09-6/BI  
(866443-09-6/RN)  
1 866443-10-9/BI  
(866443-10-9/RN)  
1 866443-11-0/BI  
(866443-11-0/RN)  
1 866443-12-1/BI  
(866443-12-1/RN)  
1 866443-13-2/BI  
(866443-13-2/RN)  
1 866443-14-3/BI  
(866443-14-3/RN)  
1 9048-63-9/BI  
(9048-63-9/RN)  
L2 42 (162425-98-1/BI OR 184488-44-6/BI OR 197508-62-6/BI OR 200960-01  
-6/BI OR 2387-23-7/BI OR 2566-89-4/BI OR 402939-18-8/BI OR 47941  
3-70-2/BI OR 564468-65-1/BI OR 776300-37-9/BI OR 866442-84-4/BI  
OR 866442-85-5/BI OR 866442-86-6/BI OR 866442-87-7/BI OR 866442-8  
8-8/BI OR 866442-89-9/BI OR 866442-90-2/BI OR 866442-91-3/BI OR  
866442-92-4/BI OR 866442-93-5/BI OR 866442-94-6/BI OR 866442-95-7

/BI OR 866442-96-8/BI OR 866442-97-9/BI OR 866442-98-0/BI OR  
866442-99-1/BI OR 866443-00-7/BI OR 866443-01-8/BI OR 866443-02-9  
/BI OR 866443-03-0/BI OR 866443-04-1/BI OR 866443-05-2/BI OR  
866443-06-3/BI OR 866443-07-4/BI OR 866443-08-5/BI OR 866443-09-6  
/BI OR 866443-10-9/BI OR 866443-11-0/BI OR 866443-12-1/BI OR  
866443-13-2/BI OR 866443-14-3/BI OR 9048-63-9/BI)

=> d 1-42

L2 ANSWER 1 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-14-3 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (A-G-A-U-G-A-C-U-C-U-C-C-A-U-A-G-C-C-U-U-U) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 8: PN: US20050222252 SEQID: 11 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-13-2 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (A-G-G-C-U-A-U-G-G-A-G-A-G-U-C-A-U-C-U-U-U) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 7: PN: US20050222252 SEQID: 10 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 3 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-12-1 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (G-A-U-G-A-C-U-C-U-C-C-A-U-A-G-C-C-U-U-U-U) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 5: PN: US20050222252 SEQID: 8 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-11-0 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (A-A-G-G-C-U-A-U-G-G-A-G-A-G-U-C-A-U-C-U-U) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 4: PN: US20050222252 SEQID: 7 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-10-9 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (A-G-U-C-A-U-G-G-C-C-A-A-U-G-A-A-C-A-C-U-U) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 2: PN: US20050222252 SEQID: 5 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-09-6 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (G-U-G-U-U-C-A-U-U-G-G-C-C-A-U-G-A-C-U-U-U) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 1: PN: US20050222252 SEQID: 4 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-08-5 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (G-C-C-C-A-C-U-U-C-C-A-G-U-U-C-C-U-U-C-C) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 18: PN: US20050222252 SEQID: 38 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE

MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 8 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-07-4 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (A-G-U-C-C-U-C-C-C-G-C-U-U-C-A-C-A-G-A) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 17: PN: US20050222252 SEQID: 37 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 9 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-06-3 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (G-U-U-C-A-G-C-C-U-C-A-G-C-C-A-C-U-C-C-U) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 16: PN: US20050222252 SEQID: 36 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 10 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-05-2 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (U-U-C-C-C-A-C-C-U-G-A-C-A-C-G-A-C-U-C-U) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 15: PN: US20050222252 SEQID: 35 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 11 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-04-1 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (U-G-U-C-C-A-G-U-G-C-C-C-A-C-A-G-U-C-C-U) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 14: PN: US20050222252 SEQID: 34 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 12 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-03-0 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN 13: PN: US20050222252 SEQID: 33 unclaimed DNA (9CI) (CA INDEX NAME)  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 13 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-02-9 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN 12: PN: US20050222252 SEQID: 32 unclaimed DNA (9CI) (CA INDEX NAME)  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 14 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-01-8 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN 10: PN: US20050222252 SEQID: 30 unclaimed DNA (9CI) (CA INDEX NAME)  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA

LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 15 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866443-00-7 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN 9: PN: US20050222252 SEQID: 29 unclaimed DNA (9CI) (CA INDEX NAME)  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 16 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-99-1 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN 13: PN: US20050222252 SEQID: 27 unclaimed DNA (9CI) (CA INDEX NAME)  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 17 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-98-0 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN 12: PN: US20050222252 SEQID: 26 unclaimed DNA (9CI) (CA INDEX NAME)  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 18 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-97-9 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN DNA, d(A-A-A-G-G-C-T-A-T-G-G-A-G-A-G-T-C-A-T-C-T-G-C) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 11: PN: US20050222252 SEQID: 25 unclaimed DNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 19 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-96-8 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN 10: PN: US20050222252 SEQID: 24 unclaimed DNA (9CI) (CA INDEX NAME)  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 20 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-95-7 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN 9: PN: US20050222252 SEQID: 23 unclaimed DNA (9CI) (CA INDEX NAME)  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 21 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-94-6 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN DNA, d(G-A-A-A-G-G-C-T-A-T-G-G-A-G-A-G-T-C-A-T-C-T-G) (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 8: PN: US20050222252 SEQID: 22 unclaimed DNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*

\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 22 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-93-5 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN 7: PN: US20050222252 SEQID: 21 unclaimed DNA (9CI) (CA INDEX NAME)  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 23 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-92-4 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN 6: PN: US20050222252 SEQID: 20 unclaimed DNA (9CI) (CA INDEX NAME)  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 24 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-91-3 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN DNA, d(C-A-G-T-G-T-T-C-A-T-T-G-G-C-C-A-T-G-A-C-T-G-G) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 5: PN: US20050222252 SEQID: 19 unclaimed DNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
1 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 25 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-90-2 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN DNA, d(T-T-C-A-A-G-A-G-A) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 4: PN: US20050222252 SEQID: 18 unclaimed DNA  
FS NUCLEIC ACID SEQUENCE

MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 26 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-89-9 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (A-A-U-C-C-A-G-U-C-C-U-C-A-U-G-U-G-C-U-U) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 3: PN: US20050222252 SEQID: 17 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 27 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-88-8 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (G-C-A-C-A-U-G-G-A-G-G-A-C-U-G-G-A-U-U-U-U) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 2: PN: US20050222252 SEQID: 16 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 28 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-87-7 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN DNA, d(C-A-G-C-A-C-A-T-G-G-A-G-G-A-C-T-G-G-A-T-T-C-C) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 1: PN: US20050222252 SEQID: 15 unclaimed DNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 29 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-86-6 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (A-U-G-G-C-C-A-A-U-G-A-A-C-A-C-U-G-C-U-U-U) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 3: PN: US20050222252 SEQID: 14 unclaimed RNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 30 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-85-5 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN RNA, (A-G-C-A-G-U-G-U-U-C-A-U-U-G-G-C-C-A-U-U-U) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 2: PN: US20050222252 SEQID: 13 unclaimed DNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2 ANSWER 31 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 866442-84-4 REGISTRY  
ED Entered STN: 31 Oct 2005  
CN DNA, d(C-A-A-G-C-A-G-T-G-T-T-C-A-T-T-G-G-C-C-A-T-G-A) (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN 1: PN: US20050222252 SEQID: 12 unclaimed DNA  
FS NUCLEIC ACID SEQUENCE  
MF Unspecified  
CI MAN  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

\*\*RELATED SEQUENCES AVAILABLE WITH SEQLINK\*\*

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*  
\*\*\* USE 'SQD' OR 'SQIDE' FORMATS TO DISPLAY SEQUENCE \*\*\*  
    1 REFERENCES IN FILE CA (1907 TO DATE)  
    1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 32 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 776300-37-9 REGISTRY


ED    Entered STN: 08 Nov 2004  
 CN    Dodecanoic acid, 12-[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-,  
       butyl ester (9CI) (CA INDEX NAME)  
 FS    3D CONCORD  
 MF    C27 H48 N2 O3  
 SR    CA  
 LC    STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

7 REFERENCES IN FILE CA (1907 TO DATE)  
 7 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2    ANSWER 33 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN    564468-65-1 REGISTRY  
 ED    Entered STN: 11 Aug 2003  
 CN    Urea, N-dodecyl-N'-tricyclo[3.3.1.13,7]dec-1-yl- (9CI) (CA INDEX NAME)  
 FS    3D CONCORD  
 MF    C23 H42 N2 O  
 SR    CA  
 LC    STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

5 REFERENCES IN FILE CA (1907 TO DATE)  
 5 REFERENCES IN FILE CAPLUS (1907 TO DATE)


L2    ANSWER 34 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
 RN    479413-70-2 REGISTRY  
 ED    Entered STN: 17 Jan 2003  
 CN    Dodecanoic acid, 12-[(tricyclo[3.3.1.13,7]dec-1-ylamino)carbonyl]amino]-  
       (9CI) (CA INDEX NAME)  
 FS    3D CONCORD  
 MF    C23 H40 N2 O3  
 SR    CA  
 LC    STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

10 REFERENCES IN FILE CA (1907 TO DATE)  
10 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 35 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 402939-18-8 REGISTRY  
ED Entered STN: 27 Mar 2002  
CN Urea, N-cyclohexyl-N'-dodecyl- (9CI) (CA INDEX NAME)  
FS 3D CONCORD  
MF C19 H38 N2 O  
SR CA  
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

15 REFERENCES IN FILE CA (1907 TO DATE)  
15 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 36 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 200960-01-6 REGISTRY  
ED Entered STN: 05 Feb 1998  
CN 5,8-Decadienoic acid, 10-[3-(2Z)-2-octenylloxiranyl]-, (5Z,8Z)- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 5,8-Decadienoic acid, 10-[3-(2-octenyl)oxiranyl]-, [2(5Z,8Z),3(Z)]-  
[partial]-  
OTHER NAMES:  
CN 11,12-Epoxyeicosatrienoic acid  
FS STEREOSEARCH  
DR 286390-06-5  
MF C20 H32 O3  
SR CAS Client Services  
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


48 REFERENCES IN FILE CA (1907 TO DATE)  
48 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 37 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 197508-62-6 REGISTRY  
ED Entered STN: 19 Nov 1997  
CN 5,8,11-Tridecatrienoic acid, 13-(3-pentyloxiranyl)-, (5Z,8Z,11Z)- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 5,8,11-Tridecatrienoic acid, 13-(3-pentyloxiranyl)-, (all-Z)-

OTHER NAMES:

CN 14,15-Epoxyeicosatrienoic acid  
FS STEREOSEARCH  
DR 200960-02-7, 286390-07-6  
MF C20 H32 O3  
SR CA  
LC STN Files: CA, CAPLUS, CASREACT, CHEMCATS, TOXCENTER, USPATFULL

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

49 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
49 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 38 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 184488-44-6 REGISTRY  
ED Entered STN: 26 Dec 1996  
CN 5-Heptenoic acid, 7-[3-(2Z,5Z)-2,5-undecadienyl]oxiranyl-, (5Z)- (9CI)  
(CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 5-Heptenoic acid, 7-[3-(2,5-undecadienyl)oxiranyl]-, (all-Z)-  
OTHER NAMES:  
CN 8,9-Epoxyeicosatrienoic acid  
FS STEREOSEARCH  
DR 286390-05-4  
MF C20 H32 O3  
SR CA  
LC STN Files: CA, CAPLUS, CHEMCATS, TOXCENTER, USPATFULL

Double bond geometry as shown.




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

37 REFERENCES IN FILE CA (1907 TO DATE)  
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
37 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 39 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 162425-98-1 REGISTRY  
ED Entered STN: 25 Apr 1995  
CN Oxiranetridecanoic acid, 3-pentyl-, (2R,3S)- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN Oxiranetridecanoic acid, 3-pentyl-, (2R-cis)-  
FS STEREOSEARCH  
MF C20 H38 O3  
SR CA  
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 40 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 9048-63-9 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN Hydratase, epoxide (9CI) (CA INDEX NAME)  
OTHER NAMES:  
CN cis-Epoxide hydrolase  
CN E.C. 3.3.2.3  
CN E.C. 4.2.1.63  
CN Epoxide hydrase  
CN Epoxide hydratase  
CN Epoxide hydrolase  
CN Epoxide lyase  
CN Epoxyhydrolase  
CN Styrene oxide hydrolase  
CN trans-Stilbene oxide hydrolase  
CN Xenobiotic epoxide hydrolase  
MF Unspecified  
CI MAN  
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS,  
CASREACT, CHEMINFORMRX, CIN, CSCHEM, EMBASE, NAPRALERT, PROMT,  
TOXCENTER, USPAT2, USPATFULL

\*\*\* STRUCTURE DIAGRAM IS NOT AVAILABLE \*\*\*


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2575 REFERENCES IN FILE CA (1907 TO DATE)  
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
2580 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 41 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN  
RN 2566-89-4 REGISTRY  
ED Entered STN: 16 Nov 1984  
CN 5,8,11,14-Eicosatetraenoic acid, methyl ester, (5Z,8Z,11Z,14Z)- (9CI) (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 5,8,11,14-Eicosatetraenoic acid, methyl ester, (all-Z)- (8CI)  
CN Arachidonic acid, methyl ester (6CI, 7CI)  
OTHER NAMES:  
CN Methyl 5Z,8Z,11Z,14Z-eicosatetraenoate  
CN Methyl all-cis-5,8,11,14-eicosatetraenoate  
CN Methyl arachidonate  
CN Methyl cis,cis,cis,cis-eicosa-5,8,11,14-tetraenoate  
FS STEREOSEARCH  
DR 2463-04-9  
MF C21 H34 O2  
CI COM  
LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, CA, CAOLD, CAPLUS,  
CASREACT, CHEMCATS, CHEMLIST, CSCHEM, EMBASE, IFICDB, IFIPAT, IFIUDB,  
NAPRALERT, PROMT, SPECINFO, TOXCENTER, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: DSL\*\*, EINECS\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

329 REFERENCES IN FILE CA (1907 TO DATE)  
14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
329 REFERENCES IN FILE CPLUS (1907 TO DATE)  
39 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L2 ANSWER 42 OF 42 REGISTRY COPYRIGHT 2006 ACS on STN

RN 2387-23-7 REGISTRY

ED Entered STN: 16 Nov 1984

CN Urea, N,N'-dicyclohexyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Urea, 1,3-dicyclohexyl- (6CI, 7CI, 8CI)

OTHER NAMES:

CN 1,3-Dicyclohexylurea

CN Dicyclohexylcarbodiamide

CN N,N'-Dicyclohexylurea

CN NSC 17013

CN NSC 30023

FS 3D CONCORD

MF C13 H24 N2 O


CI COM

LC STN Files: AGRICOLA, BEILSTEIN\*, BIOSIS, CA, CAOLD, CPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, GMELIN\*, IFICDB, IFIPAT, IFIUDB, MEDLINE, MSDS-OHS, SPECINFO, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, NDSL\*\*, TSCA\*\*

(\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

411 REFERENCES IN FILE CA (1907 TO DATE)  
10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
414 REFERENCES IN FILE CPLUS (1907 TO DATE)  
44 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	82.88	85.58

STN INTERNATIONAL LOGOFF AT 07:37:59 ON 02 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptamxg1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \*    Welcome to STN International    \* \* \* \* \* \* \* \* \*

NEWS 1            Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2            "Ask CAS" for self-help around the clock  
NEWS 3 DEC 23     New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/  
                  USPAT2  
NEWS 4 JAN 13     IPC 8 searching in IFIPAT, IFIUDB, and IFICDB  
NEWS 5 JAN 13     New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to  
                  INPADOC  
NEWS 6 JAN 17     Pre-1988 INPI data added to MARPAT  
NEWS 7 JAN 17     IPC 8 in the WPI family of databases including WPIFV  
NEWS 8 JAN 30     Saved answer limit increased  
NEWS 9 FEB 21     STN AnaVist, Version 1.1, lets you share your STN AnaVist  
                  visualization results  
NEWS 10 FEB 22    The IPC thesaurus added to additional patent databases on STN  
NEWS 11 FEB 22    Updates in EPFULL; IPC 8 enhancements added  
NEWS 12 FEB 27    New STN AnaVist pricing effective March 1, 2006  
NEWS 13 FEB 28    MEDLINE/LMEDLINE reload improves functionality  
NEWS 14 FEB 28    TOXCENTER reloaded with enhancements  
NEWS 15 FEB 28    REGISTRY/ZREGISTRY enhanced with more experimental spectral  
                  property data  
NEWS 16 MAR 01    INSPEC reloaded and enhanced  
NEWS 17 MAR 03    Updates in PATDPA; addition of IPC 8 data without attributes  
NEWS 18 MAR 08    X.25 communication option no longer available after June 2006  
NEWS 19 MAR 22    EMBASE is now updated on a daily basis  
NEWS 20 APR 03    New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 21 APR 03    Bibliographic data updates resume; new IPC 8 fields and IPC  
                  thesaurus added in PCTFULL  
NEWS 22 APR 04    STN AnaVist \$500 visualization usage credit offered  
NEWS 23 APR 12    LINSPEC, learning database for INSPEC, reloaded and enhanced  
NEWS 24 APR 12    Improved structure highlighting in FQHIT and QHIT display  
                  in MARPAT  
NEWS 25 APR 12    Derwent World Patents Index to be reloaded and enhanced during  
                  second quarter; strategies may be affected  
  
NEWS EXPRESS    FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
                  CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
                  AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
                  V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT

<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

FILE 'HOME' ENTERED AT 13:21:32 ON 02 MAY 2006

=> s 2387-23-7/rn or 402939-18-8/rn

THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE

Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> file caplus  
COST IN U.S. DOLLARS  
  
FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
0 21	0 21

FILE 'CAPLUS' ENTERED AT 13:22:09 ON 02 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2006 VOL 144 ISS 19  
FILE LAST UPDATED: 1 May 2006 (20060501/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 2387-23-7/rn or 402939-18-8/rn  
414 2387-23-7  
10 2387-23-7D  
405 2387-23-7/RN  
(2387-23-7 (NOTL) 2387-23-7D )  
15 402939-18-8  
0 402939-18-8D  
15 402939-18-8/RN  
(402939-18-8 (NOTL) 402939-18-8D )  
L1 413 2387-23-7/RN OR 402939-18-8/RN

=> s 197508-62-6/rn or 184488-44-6/rn or 200960-01-6/rn  
49 197508-62-6  
1 197508-62-6D  
48 197508-62-6/RN  
(197508-62-6 (NOTL) 197508-62-6D )  
37 184488-44-6  
1 184488-44-6D  
36 184488-44-6/RN  
(184488-44-6 (NOTL) 184488-44-6D )  
48 200960-01-6  
0 200960-01-6D  
48 200960-01-6/RN  
(200960-01-6 (NOTL) 200960-01-6D )  
L2 62 197508-62-6/RN OR 184488-44-6/RN OR 200960-01-6/RN

=> s 11 and 12  
L3 3 L1 AND L2

=> d 1-3 bib abs hitstr

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2005:1078270 CAPLUS  
DN 143:360111  
TI Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils  
IN Hammock, Bruce D.; Pinkerton, Kent E.; Smith, Kevin R.; Watanabe, Takaho; Ma, Seung Jin  
PA The Regents of the University of California, USA  
SO U.S. Pat. Appl. Publ., 32 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005222252	A1	20051006	US 2004-815425	20040331
	WO 2005094373	A2	20051013	WO 2005-US10781	20050331
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK				

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2004-815425 A 20040331

AB It has now been discovered that inhibitors of soluble epoxide hydrolase ("sEH") are useful in reducing the severity of or inhibiting the progression of obstructive pulmonary diseases, restrictive airway diseases, and asthma. Administering a cis-epoxyeicosatrienoic acid ("EET") in addition to the inhibitor is at least additive, and may be synergistic, in reducing or inhibiting these conditions and diseases, as measured by reduced nos. of neutrophils present in the lung. The inhibitor of sEH may be a nucleic acid, such as a small interfering RNA.


IT 184488-44-6, 8,9-Epoxyeicosatrienoic acid 197508-62-6,  
14,15-Epoxyeicosatrienoic acid 200960-01-6, 11,12-Epoxyeicosatrienoic acid

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(use of epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils)

RN 184488-44-6 CAPLUS

CN 5-Heptenoic acid, 7-[3-(2Z,5Z)-2,5-undecadienyloxiranyl]-, (5Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 197508-62-6 CAPLUS

CN 5,8,11-Tridecatrienoic acid, 13-(3-pentyloxiranyl)-, (5Z,8Z,11Z)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 200960-01-6 CAPLUS

CN 5,8-Decadienoic acid, 10-[3-(2Z)-2-octenyloxiranyl]-, (5Z,8Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 2387-23-7, N,N'-Dicyclohexylurea 402939-18-8


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(use of epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils)

RN 2387-23-7 CAPLUS

CN Urea, N,N'-dicyclohexyl- (9CI) (CA INDEX NAME)




RN 402939-18-8 CAPLUS  
CN Urea, N-cyclohexyl-N'-dodecyl- (9CI) (CA INDEX NAME)



L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:304495 CAPLUS  
DN 142:86167  
TI Soluble Epoxide Hydrolase Inhibition Protects the Kidney from Hypertension-Induced Damage  
AU Zhao, Xueying; Yamamoto, Tatsuo; Newman, John W.; Kim, In-Hae; Watanabe, Takaho; Hammock, Bruce D.; Stewart, Janet; Pollock, Jennifer S.; Pollock, David M.; Imig, John D.  
CS Vascular Biology Center, Medical College of Georgia, Augusta, GA, USA  
SO Journal of the American Society of Nephrology (2004), 15(5), 1244-1253  
CODEN: JASNEU; ISSN: 1046-6673  
PB Lippincott Williams & Wilkins  
DT Journal  
LA English  
AB Epoxyeicosatrienoic acids (EET) have antihypertensive and anti-inflammatory properties and play a role in the maintenance of renal vascular function. A novel approach to increase EET levels is to inhibit epoxide hydrolase enzymes that are responsible for conversion of biol. active EET to dihydroxyeicosatrienoic acids (DHET). We hypothesized that soluble epoxide hydrolase (SEH) inhibition would improve renal vascular function and ameliorate hypertension induced renal damage. Chronic administration of the specific SEH inhibitor 1-cyclohexyl-3-dodecylurea (CDU, 3 mg/d) for 10 d lowered BP in angiotensin hypertensive rats. The contribution of renal vascular SEH to afferent arteriolar function in angiotensin hypertension was also assessed. SEH protein expression was increased in renal microvessels from hypertensive rats. Although CDU did not change afferent arteriolar responsiveness to angiotensin in normotensive animals, CDU treatment significantly attenuated afferent arteriolar diameter responses to angiotensin in hypertensive kidneys from 51% ± 8% to 28% ± 7%. Protection of the renal vasculature and glomerulus during chronic CDU administration was demonstrated by histol. Urinary albumin excretion, an index of renal damage, was also lower in CDU-treated hypertensive rats. These data demonstrate that SEH inhibition has antihypertensive and renal vascular protective effects in angiotensin hypertension and suggests that SEH inhibitors may be a useful therapeutic intervention for cardiovascular diseases.  
IT 184488-44-6, 8,9-Epoxyeicosatrienoic acid 197508-62-6,  
14,15-Epoxyeicosatrienoic acid 200960-01-6, 11,12-Epoxyeicosatrienoic acid  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(chronic administration of SEH inhibitor CDU did not altered heart rate in hypertension induced rat kidney)  
RN 184488-44-6 CAPLUS  
CN 5-Heptenoic acid, 7-[3-(2Z,5Z)-2,5-undecadienyloxiranyl]-, (5Z)- (9CI)

(CA INDEX NAME)


Double bond geometry as shown.



RN 197508-62-6 CAPLUS

CN 5,8,11-Tridecatrienoic acid, 13-(3-pentyloxiranyl)-, (5Z,8Z,11Z)- (9CI)  
(CA INDEX NAME)


Double bond geometry as shown.



RN 200960-01-6 CAPLUS

CN 5,8-Decadienoic acid, 10-[3-(2Z)-2-octenylloxiranyl]-, (5Z,8Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 402939-18-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(chronic administration of SEH inhibitor CDU lowered blood pressure, raised EET, EPOME, EET:DHET ratio, reduced DHOME, urinary albumin excretion indicating antihypertensive, renal vascular protective effect in hypertension induced rat kidney)

RN 402939-18-8 CAPLUS

CN Urea, N-cyclohexyl-N'-dodecyl- (9CI) (CA INDEX NAME)



RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2001:367801 CAPLUS

DN 135:135057


TI Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition

AU Fang, Xiang; Kaduce, Terry L.; Weintraub, Neal L.; Harmon, Shawn; Teesch, Lynn M.; Morrisseau, Christophe; Thompson, David A.; Hammock, Bruce D.; Spector, Arthur A.

CS Department of Biochemistry, College of Medicine, University of Iowa, Iowa City, IA, 52242, USA  
 SO Journal of Biological Chemistry (2001), 276(18), 14867-14874  
 CODEN: JBCHA3; ISSN: 0021-9258  
 PB American Society for Biochemistry and Molecular Biology  
 DT Journal  
 LA English  
 AB Epoxyeicosatrienoic acids (EETs) are products of cytochrome P 450 epoxygenase that possess important vasodilating and anti-inflammatory properties. EETs are converted to the corresponding dihydroxyeicosatrienoic acid (DHET) by soluble epoxide hydrolase (sEH) in mammalian tissues, and inhibition of sEH has been proposed as a novel approach for the treatment of hypertension. The authors observed that sEH is present in porcine coronary endothelial cells (PCEC), and the authors found that low concns. of N,N'-dicyclohexylurea (DCU), a selective sEH inhibitor, have profound effects on EET metabolism in PCEC cultures. Treatment with 3  $\mu$ M DCU reduced cellular conversion of 14,15-EET to 14,15-DHET by 3-fold after 4 h of incubation, with a concomitant increase in the formation of the novel  $\beta$ -oxidation products 10,11-epoxy-16:2 and 8,9-epoxy-14:1. DCU also markedly enhanced the incorporation of 14,15-EET and its metabolites into PCEC lipids. The most abundant product in DCU-treated cells was 16,17-epoxy-22:3, the elongation product of 14,15-EET. Another novel metabolite, 14,15-epoxy-20:2, was present in DCU-treated cells. DCU also caused a 4-fold increase in release of 14,15-EET when the cells were stimulated with a calcium ionophore. Furthermore, DCU decreased the conversion of [3H]11,12-EET to 11,12-DHET, increased 11,12-EET retention in PCEC lipids, and produced an accumulation of the partial  $\beta$ -oxidation product 7,8-epoxy-16:2 in the medium. These findings suggest that in addition to being metabolized by sEH, EETs are substrates for  $\beta$ -oxidation and chain elongation in endothelial cells and that there is considerable interaction among the three pathways. The modulation of EET metabolism by DCU provides novel insight into the mechanisms by which pharmacol. or mol. inhibition of sEH effectively treats hypertension.


IT 197508-62-6  
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (pathways of epoxyeicosatrienoic acid metabolism in porcine coronary endothelial cells in relation to implications for vascular effects of soluble epoxide hydrolase inhibition)  
 RN 197508-62-6 CAPLUS  
 CN 5,8,11-Tridecatrienoic acid, 13-(3-pentyloxiranyl)-, (5Z,8Z,11Z)- (9CI)  
 (CA INDEX NAME)

Double bond geometry as shown.




IT 200960-01-6  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
 (pathways of epoxyeicosatrienoic acid metabolism in porcine coronary endothelial cells in relation to implications for vascular effects of soluble epoxide hydrolase inhibition)  
 RN 200960-01-6 CAPLUS  
 CN 5,8-Decadienoic acid, 10-[3-(2Z)-2-octenylloxiranyl]-, (5Z,8Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 2387-23-7, N,N'-Dicyclohexylurea  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (pathways of epoxyeicosatrienoic acid metabolism in porcine coronary  
 endothelial cells in relation to implications for vascular effects of  
 soluble epoxide hydrolase inhibition)  
 RN 2387-23-7 CAPLUS  
 CN Urea, N,N'-dicyclohexyl- (9CI) (CA INDEX NAME)



RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 11 and (respiratory or pulmonary)

116642 RESPIRATORY  
 80523 PULMONARY

L4 6 L1 AND (RESPIRATORY OR PULMONARY)

=> d 1-6 bib abs hitstr

L4 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1078270 CAPLUS

DN 143:360111

TI Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils

IN Hammock, Bruce D.; Pinkerton, Kent E.; Smith, Kevin R.; Watanabe, Takaho; Ma, Seung Jin

PA The Regents of the University of California, USA

SO U.S. Pat. Appl. Publ., 32 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005222252	A1	20051006	US 2004-815425	20040331
	WO 2005094373	A2	20051013	WO 2005-US10781	20050331
		W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW		
		RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		

PRAI US 2004-815425 A 20040331

AB It has now been discovered that inhibitors of soluble epoxide hydrolase ("sEH") are useful in reducing the severity of or inhibiting the

progression of obstructive pulmonary diseases, restrictive airway diseases, and asthma. Administering a cis-epoxyeicosatrienoic acid ("EET") in addition to the inhibitor is at least additive, and may be synergistic, in reducing or inhibiting these conditions and diseases, as measured by reduced nos. of neutrophils present in the lung. The inhibitor of sEH may be a nucleic acid, such as a small interfering RNA.


IT 2387-23-7, N,N'-Dicyclohexylurea 402939-18-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils)


RN 2387-23-7 CAPLUS

CN Urea, N,N'-dicyclohexyl- (9CI) (CA INDEX NAME)



RN 402939-18-8 CAPLUS

CN Urea, N-cyclohexyl-N'-dodecyl- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:672863 CAPLUS

DN 143:172556

TI Inhibitors for the soluble epoxide hydrolase

IN Hammock, Bruce D.; Kim, In-Hae; Morisseau, Christophe; Watanabe, Takaho; Newman, John W.

PA The Regents of the University of California, USA

SO U.S. Pat. Appl. Publ., 117 pp., Cont.-in-part of U.S. Ser. No. 817,334.  
CODEN: USXXCO

DT Patent


LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005164951	A1	20050728	US 2004-970373	20041020
	US 2005026844	A1	20050203	US 2004-817334	20040402
PRAI	US 2003-460559P	P	20030403		
	US 2004-817334	A2	20040402		

OS MARPAT 143:172556

GI



I

AB Inhibitors of the soluble epoxide hydrolase (sEH), R<sub>1</sub>-P<sub>1</sub>-L<sub>1</sub>-(P<sub>2</sub>)<sub>n</sub>-L<sub>2</sub>-(P<sub>3</sub>)<sub>m</sub> (R<sub>1</sub> = substituted or unsubstituted alkyl, heteroalkyl, cycloalkyl, arylalkyl, heteroaryl, etc.; P<sub>1</sub> = carbamate, ester amide, urea, etc., P<sub>2</sub> = NH, carbamate, CO, -CH(OH)-, etc., P<sub>3</sub> = alkenyl, alkynyl, aryl, heteroaryl, heterocycle, ester, amide, etc., m and n = integers) are provided that incorporate multiple pharmacophores and are useful in the treatment of related diseases. Thus, treatment of benzophenone imine and Et 4-aminobutyrate hydrochloride in methylene chloride gave the benzophenone Schiff base which was then treated with hexylbromide at room temperature to give the alc. The above alc. was treated with acetic anhydride in DMSO to give the corresponding ketone. Reaction of the ketone product with 1N HCl in dioxane gave keto amine hydrochloride which was dissolved in DMF and treated with triethylamine and 3-chlorophenylisocyante to give I which had and IC<sub>50</sub> values of 0.41±0.05 μM and 2.1±0.2 μM against mouse and human soluble epoxide hydrolases resp.


IT 402939-18-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of inhibitors for the soluble epoxide hydrolase for the treatment of related diseases)

RN 402939-18-8 CAPLUS

CN Urea, N-cyclohexyl-N'-dodecyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:872659 CAPLUS

DN 141:343446

TI Preparation of soluble epoxide hydrolase inhibitors

IN Hammock, Bruce D.; Kim, In-Hae; Morisseau, Christophe; Watanabe, Takaho; Newman, John W.

PA The Regents of the University of California, USA

SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089296	A2	20041021	WO 2004-US10298	20040402
	WO 2004089296	A3	20060309		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004228028	A1	20041021	AU 2004-228028	20040402

CA 2520763 AA 20041021 CA 2004-2520763 20040402  
 EP 1608319 A2 20051228 EP 2004-758831 20040402  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR  
 PRAI US 2003-460559P P 20030403  
 WO 2004-US10298 W 20040402

**AB** Inhibitors of the soluble epoxide hydrolase (sEH) incorporating multiple pharmacophores are prepared for use in the treatment of diseases. The compds. used were, e.g., substituted ureas. Thus, 1-(1-adamantyl)-3-(11-tert-butoxycarbonylundecyl)urea (I), was prepared in a series of steps starting from 1-adamantyl isocyanate and 12-aminododecanoic acid followed by treatment with tert-BuOH. The effectiveness of I in the inhibition of mouse and human soluble epoxide hydrolase was demonstrated.


IT 402939-18-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of soluble epoxide hydrolase inhibitors)

RN 402939-18-8 CAPLUS


CN Urea, N-cyclohexyl-N'-dodecyl- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2000:821596 CAPLUS  
 DN 133:349972  
 TI Preparation of ureas and related compounds as soluble epoxide hydrolase inhibitors.  
 IN Hammock, Bruce D.; Morisseau, Christophe H.; Zheng, Jiang; Goodrow, Marvin H.; Severson, Tonya; Sanborn, James  
 PA The Regents of the University of California, USA  
 SO U.S., 17 pp., Cont.-in-part of U. S. 5,955,496.  
 CODEN: USXXAM  
 DT Patent  
 LA English  
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6150415	A	20001121	US 1999-252148	19990218
	US 5955496	A	19990921	US 1997-909523	19970812
	ES 2221064	T3	20041216	ES 1997-938335	19970813
	US 6174695	B1	20010116	US 1999-312207	19990514
	CA 2362331	AA	20000824	CA 2000-2362331	20000210
	WO 2000048593	A1	20000824	WO 2000-US3495	20000210
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1154764	A1	20011121	EP 2000-911767	20000210
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002540767	T2	20021203	JP 2000-599385	20000210

US 6531506	B1	20030311	US 2000-721261	20001121
US 2003119900	A1	20030626	US 2002-328495	20021223
US 6693130	B2	20040217		
US 2004092487	A1	20040513	US 2003-694641	20031027
US 2005282767	A1	20051222	US 2005-189964	20050725
US 2006035869	A1	20060216	US 2005-240444	20050929
PRAI US 1996-23397P	P	19960813		
US 1997-909523	A2	19970812		
US 1999-252148	A	19990218		
WO 2000-US3495	W	20000210		
US 2000-721261	A1	20001121		
US 2002-328495	A1	20021223		
US 2003-694641	A1	20031027		
OS MARPAT 133:349972				
AB R1R2XCOYR3R4 [I; X = C, O, N, S; Y = N, O, S; ≥1 of R1-R4 = H; R2 = H when X = N, R2 = null when X = S, O; R4 = H when Y = N, R4 = null when Y = S, O; R1, R3 = (substituted) alkyl, haloalkyl, cycloalkyl, aryl, acyl, heterocycl; and metabolites and degradation products thereof], were prepared Thus, pentylamine in hexane was treated with octyl isocyanate followed by stirring and standing overnight to give 97% 1-octyl-3-pentylurea. The latter inhibited human soluble epoxide hydrolase with IC <sub>50</sub> = 0.72 μM. I may be used to purify, isolate, or inhibit epoxide hydrolase, and may be used in conjunction with herbicides, insecticides, and fungicides.				
IT 2387-23-7				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(preparation of ureas and related compds. as soluble epoxide hydrolase inhibitors)				
RN 2387-23-7 CAPLUS				
CN Urea, N,N'-dicyclohexyl- (9CI) (CA INDEX NAME)				



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 1999:503921 CAPLUS  
 DN 131:280999  
 TI Potent urea and carbamate inhibitors of soluble epoxide hydrolases  
 AU Morisseau, Christophe; Goodrow, Marvin H.; Dowdy, Deanna; Zheng, Jiang;  
 Greene, Jessica F.; Sanborn, James R.; Hammock, Bruce D.  
 CS Department of Entomology, University of California, Davis, CA, 95616, USA  
 SO Proceedings of the National Academy of Sciences of the United States of  
 America (1999), 96(16), 8849-8854  
 CODEN: PNASA6; ISSN: 0027-8424  
 PB National Academy of Sciences  
 DT Journal  
 LA English  
 AB The soluble epoxide hydrolase (sEH) plays a significant role in the biosynthesis of inflammation mediators as well as xenobiotic transformations. Herein, the authors report the discovery of substituted ureas and carbamates as potent inhibitors of sEH. Some of these selective, competitive tight-binding inhibitors with nanomolar Ki values interacted stoichiometrically with the homogeneous recombinant murine and human sEHs. These inhibitors enhance cytotoxicity of trans-stilbene oxide, which is active as the epoxide, but reduce cytotoxicity of leukotoxin, which is activated by epoxide hydrolase to its toxic diol.


They also reduce toxicity of leukotoxin in vivo in mice and prevent symptoms suggestive of acute respiratory distress syndrome.  
These potent inhibitors may be valuable tools for testing hypotheses of involvement of diol and epoxide lipids in chemical mediation in vitro or in vivo systems.

IT 2387-23-7, N,N'-Dicyclohexylurea  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(potent urea and carbamate inhibitors of soluble epoxide hydrolases in relation to structure and role of diol and epoxide lipids and treatment of acute respiratory distress syndrome)

RN 2387-23-7 CAPLUS

CN Urea, N,N'-dicyclohexyl- (9CI) (CA INDEX NAME)



RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN

AN 1976:13355 CAPLUS

DN 84:13355

TI 1,2,3-Thiadiazolyl-phenyl-ureas, new inhibitors of photosynthetic and respiratory energy conservation

AU Hauska, G.; Trebst, A.; Koetter, C.; Schulz, H.

CS Abt. Biol., Ruhr-Univ. Bochum, Bochum, Fed. Rep. Ger.

SO Zeitschrift fuer Naturforschung, C: Journal of Biosciences (1975), 30c(7-8), 505-10

CODEN: ZNCBDA; ISSN: 0939-5075

DT Journal

LA English

AB Substituted 1,2,3-thiadiazolylphenylureas such as N-3,4-dichlorophenyl-N'-1,2,3-thiadiazolylurea (I) [51707-61-0] inhibited energy conservation in respiration and photosynthesis. I, the most effective derivative, uncoupled ATP formation in isolated spinach chloroplasts or white-potato mitochondria, at a concentration of about 2 and 9 $\mu$ M resp. At a certain concentration


range the compds. are apparently energy transfer inhibitors, similar to the well known inhibition by carbodiimides. The significance of the chemical relation of carbodiimides to ureas in the mode of action on energy transfer is discussed. The thiadiazolylphenylureas were inhibitors of electron flow only at relatively high concns., pointing out that steric hindrance by two large aromatic rings at both nitrogens of the urea moiety abolished the highly effective inhibition of photosynthetic electron flow by substituted urea derivs., like DCMU [330-54-1].

IT 2387-23-7

RL: BIOL (Biological study)  
(photosynthetic and respiratory energy conservation in relation to)

RN 2387-23-7 CAPLUS

CN Urea, N,N'-dicyclohexyl- (9CI) (CA INDEX NAME)



=> s 13 and (respiratory or pulmonary)

116642 RESPIRATORY

80523 PULMONARY

L5 1 L3 AND (RESPIRATORY OR PULMONARY)

=> bib abs hitstr

BIB IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (>).

=> d bib abs hitstr

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1078270 CAPLUS

DN 143:360111

TI Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils

IN Hammock, Bruce D.; Pinkerton, Kent E.; Smith, Kevin R.; Watanabe, Takaho; Ma, Seung Jin

PA The Regents of the University of California, USA

SO U.S. Pat. Appl. Publ., 32 pp.  
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005222252	A1	20051006	US 2004-815425	20040331
	WO 2005094373	A2	20051013	WO 2005-US10781	20050331
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2004-815425 A 20040331

AB It has now been discovered that inhibitors of soluble epoxide hydrolase ("sEH") are useful in reducing the severity of or inhibiting the progression of obstructive pulmonary diseases, restrictive airway diseases, and asthma. Administering a cis-epoxyeicosatrienoic acid ("EET") in addition to the inhibitor is at least additive, and may be synergistic, in reducing or inhibiting these conditions and diseases, as measured by reduced nos. of neutrophils present in the lung. The inhibitor of sEH may be a nucleic acid, such as a small interfering RNA.

IT 184488-44-6, 8,9-Epoxyeicosatrienoic acid 197508-62-6,

14,15-Epoxyeicosatrienoic acid 200960-01-6, 11,12-Epoxyeicosatrienoic acid


RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils)

RN 184488-44-6 CAPLUS

CN 5-Heptenoic acid, 7-[3-(2Z,5Z)-2,5-undecadienyloxiranyl]-, (5Z)- (9CI)  
(CA INDEX NAME)


Double bond geometry as shown.



RN 197508-62-6 CAPLUS

CN 5,8,11-Tridecatrienoic acid, 13-(3-pentyloxiranyl)-, (5Z,8Z,11Z)- (9CI)  
(CA INDEX NAME)


Double bond geometry as shown.



RN 200960-01-6 CAPLUS

CN 5,8-Decadienoic acid, 10-[3-(2Z)-2-octenylloxiranyl]-, (5Z,8Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 2387-23-7, N,N'-Dicyclohexylurea 402939-18-8

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(use of epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils)


RN 2387-23-7 CAPLUS

CN Urea, N,N'-dicyclohexyl- (9CI) (CA INDEX NAME)



RN 402939-18-8 CAPLUS

CN Urea, N-cyclohexyl-N'-dodecyl- (9CI) (CA INDEX NAME)



=> s 13 and inflamat  
=>  
=> s 13 and inflammation  
150115 INFLAMMATION  
L6 1 L3 AND INFLAMMATION

=> s 13 and inflammatory  
155634 INFLAMMATORY  
L7 2 L3 AND INFLAMMATORY

=> d 1-2 bib abs

L7 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2004:304495 CAPLUS  
DN 142:86167  
TI Soluble Epoxide Hydrolase Inhibition Protects the Kidney from Hypertension-Induced Damage  
AU Zhao, Xueying; Yamamoto, Tatsuo; Newman, John W.; Kim, In-Hae; Watanabe, Takaho; Hammock, Bruce D.; Stewart, Janet; Pollock, Jennifer S.; Pollock, David M.; Imig, John D.  
CS Vascular Biology Center, Medical College of Georgia, Augusta, GA, USA  
SO Journal of the American Society of Nephrology (2004), 15(5), 1244-1253  
CODEN: JASNEU; ISSN: 1046-6673  
PB Lippincott Williams & Wilkins  
DT Journal  
LA English  
AB Epoxyeicosatrienoic acids (EET) have antihypertensive and anti-inflammatory properties and play a role in the maintenance of renal vascular function. A novel approach to increase EET levels is to inhibit epoxide hydrolase enzymes that are responsible for conversion of biol. active EET to dihydroxyeicosatrienoic acids (DHET). We hypothesized that soluble epoxide hydrolase (SEH) inhibition would improve renal vascular function and ameliorate hypertension induced renal damage. Chronic administration of the specific SEH inhibitor 1-cyclohexyl-3-dodecylurea (CDU, 3 mg/d) for 10 d lowered BP in angiotensin hypertensive rats. The contribution of renal vascular SEH to afferent arteriolar function in angiotensin hypertension was also assessed. SEH protein expression was increased in renal microvessels from hypertensive rats. Although CDU did not change afferent arteriolar responsiveness to angiotensin in normotensive animals, CDU treatment significantly attenuated afferent arteriolar diameter responses to angiotensin in hypertensive kidneys from 51% ± 8% to 28% ± 7%. Protection of the renal vasculature and glomerulus during chronic CDU administration was demonstrated by histol. Urinary albumin excretion, an index of renal damage, was also lower in CDU-treated hypertensive rats. These data demonstrate that SEH inhibition has antihypertensive and renal vascular protective effects in angiotensin hypertension and suggests that SEH inhibitors may be a useful therapeutic intervention for cardiovascular diseases.

RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN  
AN 2001:367801 CAPLUS  
DN 135:135057  
TI Pathways of epoxyeicosatrienoic acid metabolism in endothelial cells. Implications for the vascular effects of soluble epoxide hydrolase inhibition  
AU Fang, Xiang; Kaduce, Terry L.; Weintraub, Neal L.; Harmon, Shawn; Teesch, Lynn M.; Morisseau, Christophe; Thompson, David A.; Hammock, Bruce D.; Spector, Arthur A.  
CS Department of Biochemistry, College of Medicine, University of Iowa, Iowa City, IA, 52242, USA

SO Journal of Biological Chemistry (2001), 276(18), 14867-14874  
CODEN: JBCHA3; ISSN: 0021-9258  
PB American Society for Biochemistry and Molecular Biology  
DT Journal  
LA English  
AB Epoxyeicosatrienoic acids (EETs) are products of cytochrome P 450 epoxygenase that possess important vasodilating and anti-inflammatory properties. EETs are converted to the corresponding dihydroxyeicosatrienoic acid (DHET) by soluble epoxide hydrolase (sEH) in mammalian tissues, and inhibition of sEH has been proposed as a novel approach for the treatment of hypertension. The authors observed that sEH is present in porcine coronary endothelial cells (PCEC), and the authors found that low concns. of N,N'-dicyclohexylurea (DCU), a selective sEH inhibitor, have profound effects on EET metabolism in PCEC cultures. Treatment with 3 μM DCU reduced cellular conversion of 14,15-EET to 14,15-DHET by 3-fold after 4 h of incubation, with a concomitant increase in the formation of the novel β-oxidation products 10,11-epoxy-16:2 and 8,9-epoxy-14:1. DCU also markedly enhanced the incorporation of 14,15-EET and its metabolites into PCEC lipids. The most abundant product in DCU-treated cells was 16,17-epoxy-22:3, the elongation product of 14,15-EET. Another novel metabolite, 14,15-epoxy-20:2, was present in DCU-treated cells. DCU also caused a 4-fold increase in release of 14,15-EET when the cells were stimulated with a calcium ionophore. Furthermore, DCU decreased the conversion of [3H]11,12-EET to 11,12-DHET, increased 11,12-EET retention in PCEC lipids, and produced an accumulation of the partial β-oxidation product 7,8-epoxy-16:2 in the medium. These findings suggest that in addition to being metabolized by sEH, EETs are substrates for β-oxidation and chain elongation in endothelial cells and that there is considerable interaction among the three pathways. The modulation of EET metabolism by DCU provides novel insight into the mechanisms by which pharmacol. or mol. inhibition of sEH effectively treats hypertension.

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	108.94	109.15
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.00	-9.00

STN INTERNATIONAL LOGOFF AT 13:49:45 ON 02 MAY 2006

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssptamxg1614

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/USPAT2
NEWS	4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	8	JAN 30	Saved answer limit increased
NEWS	9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	14	FEB 28	TOXCENTER reloaded with enhancements
NEWS	15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	16	MAR 01	INSPEC reloaded and enhanced
NEWS	17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	18	MAR 08	X.25 communication option no longer available after June 2006
NEWS	19	MAR 22	EMBASE is now updated on a daily basis
NEWS	20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	22	APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected
NEWS EXPRESS			FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005. V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT <a href="http://download.cas.org/express/v8.0-Discover/">http://download.cas.org/express/v8.0-Discover/</a>
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

COMPLETE THE STN SURVEY - APRIL 27 THROUGH MAY 31

Dear valued STN customer,

In an effort to enhance your experience with STN, we would like to better understand what you find useful. Please take approximately 5 minutes to complete a web survey.

If you provide us with your name, login ID, and e-mail address, you will be entered in a drawing to win a free iPod(R). Your responses will be kept confidential and will help us make future improvements to STN.

Take survey: <http://www.zoomerang.com/survey.zgi?p=WEB2259HNKWTUW>

Thank you in advance for your participation.

FILE 'HOME' ENTERED AT 13:54:06 ON 02 MAY 2006

FILE 'CAPLUS' ENTERED AT 13:55:37 ON 02 MAY 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 May 2006 VOL 144 ISS 19  
FILE LAST UPDATED: 1 May 2006 (20060501/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 2387-23-7/rn or 402939-18-8/rn  
414 2387-23-7  
10 2387-23-7D  
405 2387-23-7/RN  
          (2387-23-7 (NOTL) 2387-23-7D )  
15 402939-18-8  
0 402939-18-8D  
15 402939-18-8/RN  
          (402939-18-8 (NOTL) 402939-18-8D )  
L1 413 2387-23-7/RN OR 402939-18-8/RN

=> s 11 and "obstructive pulmonary"

MISMATCHED QUOTE 'PULMONARY'"'

Quotation marks (or apostrophes) must be used in pairs, one before and one after the expression you are setting off or masking.

=> s l1 and "obstructive pulmonary"  
 10470 "OBSTRUCTIVE"  
 80523 "PULMONARY"  
 5098 "OBSTRUCTIVE PULMONARY"  
 ("OBSTRUCTIVE" (W) "PULMONARY")  
 L2        3 L1 AND "OBSTRUCTIVE PULMONARY"

=> d 1-3 bib abs

L2        ANSWER 1 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN      2005:1078270 CAPLUS  
 DN      143:360111  
 TI      Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce pulmonary infiltration by neutrophils  
 IN      Hammock, Bruce D.; Pinkerton, Kent E.; Smith, Kevin R.; Watanabe, Takaho; Ma, Seung Jin  
 PA      The Regents of the University of California, USA  
 SO      U.S. Pat. Appl. Publ., 32 pp.  
 CODEN: USXXCO

DT      Patent  
 LA      English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005222252	A1	20051006	US 2004-815425	20040331
	WO 2005094373	A2	20051013	WO 2005-US10781	20050331
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2004-815425        A        20040331

AB      It has now been discovered that inhibitors of soluble epoxide hydrolase ("sEH") are useful in reducing the severity of or inhibiting the progression of **obstructive pulmonary** diseases, restrictive airway diseases, and asthma. Administering a cis-epoxyeicosatrienoic acid ("EET") in addition to the inhibitor is at least additive, and may be synergistic, in reducing or inhibiting these conditions and diseases, as measured by reduced nos. of neutrophils present in the lung. The inhibitor of sEH may be a nucleic acid, such as a small interfering RNA.


L2        ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN      2005:672863 CAPLUS  
 DN      143:172556  
 TI      Inhibitors for the soluble epoxide hydrolase  
 IN      Hammock, Bruce D.; Kim, In-Hae; Morisseau, Christophe; Watanabe, Takaho; Newman, John W.  
 PA      The Regents of the University of California, USA  
 SO      U.S. Pat. Appl. Publ., 117 pp., Cont.-in-part of U.S. Ser. No. 817,334.  
 CODEN: USXXCO

DT      Patent  
 LA      English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005164951	A1	20050728	US 2004-970373	20041020
	US 2005026844	A1	20050203	US 2004-817334	20040402

PRAI US 2003-460559P P 20030403  
 US 2004-817334 A2 20040402  
 OS MARPAT 143:172556  
 GI



**AB** Inhibitors of the soluble epoxide hydrolase (sEH), R1-P1-L1-(P2)n-L2-(P3)m (R1 = substituted or unsubstituted alkyl, heteroalkyl, cycloalkyl, arylalkyl, heteroaryl, etc.; P1 = carbamate, ester amide, urea, etc., P2 = NH, carbamate, CO, -CH(OH)-, etc., P3 = alkenyl, alkynyl, aryl, heteroaryl, heterocycle, ester, amide, etc., m and n = integers) are provided that incorporate multiple pharmacophores and are useful in the treatment of related diseases. Thus, treatment of benzophenone imine and Et 4-aminobutyrate hydrochloride in methylene chloride gave the benzophenone Schiff base which was then treated with hexylbromide at room temperature to give the alc. The above alc. was treated with acetic anhydride in DMSO to give the corresponding ketone. Reaction of the ketone product with 1N HCl in dioxane gave keto amine hydrochloride which was dissolved in DMF and treated with triethylamine and 3-chlorophenylisocyanate to give I which had an IC<sub>50</sub> values of 0.41±0.05 μM and 2.1±0.2 μM against mouse and human soluble epoxide hydrolases resp.

L2 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN  
 AN 2004:872659 CAPLUS  
 DN 141:343446

TI Preparation of soluble epoxide hydrolase inhibitors

IN Hammock, Bruce D.; Kim, In-Hae; Morisseau, Christophe; Watanabe, Takaho; Newman, John W.

PA The Regents of the University of California, USA

SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004089296	A2	20041021	WO 2004-US10298	20040402
	WO 2004089296	A3	20060309		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004228028	A1	20041021	AU 2004-228028	20040402
	CA 2520763	AA	20041021	CA 2004-2520763	20040402
	EP 1608319	A2	20051228	EP 2004-758831	20040402
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRAI US 2003-460559P	P	20030403			

WO 2004-US10298 W 20040402

AB Inhibitors of the soluble epoxide hydrolase (sEH) incorporating multiple pharmacophores are prepared for use in the treatment of diseases. The compds. used were, e.g., substituted ureas. Thus, 1-(1-adamantyl)-3-(11-tert-butoxycarbonylundecyl)urea (I), was prepared in a series of steps starting from 1-adamantyl isocyanate and 12-aminododecanoic acid followed by treatment with tert-BuOH. The effectiveness of I in the inhibition of mouse and human soluble epoxide hydrolase was demonstrated.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	20.84	21.47
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

STN INTERNATIONAL LOGOFF AT 13:56:57 ON 02 MAY 2006